Vildagliptin and its metabolite M20.7 induce the expression of S100A8 and S100A9 in human hepatoma HepG2 and leukemia HL-60 cells

Vildagliptin is a potent, orally active inhibitor of dipeptidyl peptidase-4 (DPP-4) for the treatment of type 2 diabetes mellitus. It has been reported that vildagliptin can cause hepatic dysfunction in patients. However, the molecular-mechanism of vildagliptin-induced liver dysfunction has not been...

Descripción completa

Detalles Bibliográficos
Autores principales: Asakura, Mitsutoshi, Karaki, Fumika, Fujii, Hideaki, Atsuda, Koichiro, Itoh, Tomoo, Fujiwara, Ryoichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069476/
https://www.ncbi.nlm.nih.gov/pubmed/27759084
http://dx.doi.org/10.1038/srep35633

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069476/
https://www.ncbi.nlm.nih.gov/pubmed/27759084
http://dx.doi.org/10.1038/srep35633

Ejemplares similares